贝伐珠单抗经脑膜中动脉灌注治疗慢性硬膜下血肿:25例35个半球的影像与临床结局
该扩展病例系列纳入25例无症状或症状轻微的慢性硬膜下血肿成人患者,对35个受累半球在透视引导下经脑膜中动脉行贝伐珠单抗动脉内灌注。主要终点为90天时血肿体积缩小百分比,结果显示80%(28/35)的半球血肿缩小超过50%,25.7%(9/35)完全吸收,90天内无因症状复发需补救干预、新发卒中或神经功能恶化及死亡。提示该血管内灌注方式在特定患者中具有潜在应用价值。
要点
- 经脑膜中动脉灌注贝伐珠单抗后,90天时80%的半球血肿缩小超过50%。
- 本组病例90天内无因症状复发需补救干预、新发卒中或死亡。
- 入选患者为无症状或症状轻微、CT呈混合密度或可见包膜的慢性硬膜下血肿。
核心结论
- 经脑膜中动脉动脉内灌注贝伐珠单抗在特定慢性硬膜下血肿患者中显示出促进血肿吸收的潜力。
研究设计与样本
- 扩展病例系列,纳入25例成人患者共35个受累半球,在透视引导下经一侧或双侧脑膜中动脉灌注贝伐珠单抗。
- 入选标准为无症状或症状轻微的成人单侧或双侧慢性硬膜下血肿,CT表现为混合密度或存在包膜。
- 主要终点为从基线至90天随访时血肿体积缩小的百分比;患者中位年龄77岁(IQR 68-86)。
关键影像表现/征象
- 入选血肿的CT表现为混合密度或可见包膜,但原文未进一步描述具体影像征象细节。
诊断标准与关键数值
- 90天随访时80%(28/35)的半球血肿缩小超过50%,25.7%(9/35)的半球血肿完全吸收(100%缩小)。
临床应用与阅片要点
- 对于无症状或症状轻微、CT呈混合密度或可见包膜的慢性硬膜下血肿,可关注经脑膜中动脉灌注贝伐珠单抗这一探索性治疗选项。
- 随访评估应以90天时血肿体积缩小百分比为主要影像指标,注意本组多数半球缩小超过50%但完全吸收比例较低。
局限性
- 本文为病例系列,未设对照组,样本量有限(25例35个半球)。
- 原文仅报告90天随访结局,缺乏更长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Bevacizumab is an anti-vascular endothelial growth factor antibody that may disrupt the pro-inflammatory cascade driving chronic subdural hematoma (CSDH) development, expansion, and recurrence. This expanded case series describes clinical and radiographic outcomes of intra-arterial infusion of bevacizumab into the middle meningeal artery for treatment of chronic subdural hematoma in 35 hemispheres of 25 patients. Adult patients with asymptomatic or mild symptoms and either unilateral or bilateral CSDH with mixed-density appearance or presence of membranes infused with intra-arterial bevacizumab in one or both middle meningeal arteries under fluoroscopic guidance were included. The primary outcome was the percent reduction in CSDH size from baseline to 90-day follow-up. Of 25 included patients, median age was 77 years (IQR 68-86). Of 35 treated hemispheres, 80% (28/35) hemispheres demonstrated greater than 50% CSDH resolution, and 25.7% (9/35) hemispheres had 100% resolution by 90 days. There were no rescue interventions for symptomatic recurrence, new stroke or neurological deterioration, or mortality by 90 days. In conclusion, intra-arterial bevacizumab infusion demonstrates potential as a novel endovascular approach to CSDH in select patients.
引用
- Thomas AJ, Khalife J, Shaikh HA, et al. Bevacizumab Infusion into Middle Meningeal Arteries for Chronic Subdural Hematoma: Insights from 35 Hemispheres in 25 Patients. AJNR Am J Neuroradiol. 2026. PMID: 42855269. doi:10.3174/ajnr.A9655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。